Alternate Health announces first-ever American Medical Association (AMA) approved Cannabis and Chronic Traumatic Encephalopathy (CTE) Treatment for Continuing Medical Education accreditation.

Toronto, ON, May 11, 2017 – Alternate Health Corp (CSE:AHG) (OTC:AHGIF) announced today that its Continuing Medical Education (CME) program for doctors on Chronic Traumatic Encephalopathy (CTE) and Cannabis has been approved and accepted by the Accreditation Council for Continuing Medical Education (ACCME) in partnership with the American Medical Association (AMA). Through the course, doctors learn the latest techniques and breakthroughs in CTE research, and fulfill their CME requirements at the same time.

“We are extremely excited to add this CTE protocol to our existing library of medical cannabis accredited courses,” says Dr. Jamison Feramisco, CEO of Alternate Health Corp. “Through our partnership with the University of Louisville, we have created an educational series that instructs doctors how to use cannabis as an emerging treatment for CTE and other medical disorders.”

In order to demonstrate the quality and comprehensive nature of this program, Alternate Health has included an introductory video (https://vimeo.com/216875569) of the Chronic Traumatic Encephalopathy (CTE) and Cannabis Course, and will commence sales of the online course on our website (www.alternatemedical.com) and at events across the United States and Canada.

CTE is a progressive degenerative disorder found in people who have suffered brain trauma through repeated concussions, micro-concussions or blows to the head. The disorder gained recognition through high-profile cases in athletes, like NFL players or boxers, who have suffered recurrent injuries throughout their careers. Signs of CTE usually begin to show 8-10 years later, with symptoms ranging from dizziness and memory loss to vertigo and dementia.

Launched through Alternate Health’s subsidiary, Alternate Medical Media, the CTE and Cannabis course is the first CME of its kind recognized by the AMA. The course builds on Alternate Medical Media’s previously AMA-approved course on The Endocannabinoid System and Cannabidiol (CBD) and continues to strengthen the company’s research and education assets.

“We will continue to publish high quality educational programs for physicians and those in the cannabis industry who wish to know the science behind the body’s endocannabinoid system,” says Dr. Feramisco. “Alternate Health’s CME courses are set to lead the discussion on how to use cannabis in treating a wide range of ailments.”
These CME programs will be available to doctors, scientists and the public online at www.AlternateMedical.com and offer full accreditation and certificate level courses on medical distribution, deployment and the delivery of CBD and THC.

About Alternate Health Corp.
Alternate Health Corp. is a technology-focused healthcare company, driving innovation in complementary medicine, clinical research and medical cannabis. Based on a portfolio of clinical laboratories, research studies and medical software, Alternate Health invests in research, testing and production for the medicinal and therapeutic use of Cannabidiol (CBD) and other cannabinoids. Leveraging the company’s assets in exclusive patents and partnerships, Alternate Health positions itself to be the global authority on the science, manufacturing and administration of medical cannabis.

Contact:
Graham Buck: Graham.Buck@finsbury.com
Alex Kovtun: Alex.Kovtun@finsbury.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.